Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using induced pluripotent stem cell (iPSC) technology to treat cancer and autoimmune diseases. The company's pipeline includes FT819, an off-the-shelf CAR T-cell candidate for systemic lupus erythematosus and other autoimmune conditions, which has demonstrated rapid B-cell depletion and durable clinical responses in Phase 1 studies with reduced or eliminated conditioning chemotherapy requirements. Additional programs include FT825 and FT836 for various solid tumors and hematologic cancers, and FT522 for B-cell lymphoma. Fate Therapeutics' approach focuses on multiplexed-engineered cell products designed to overcome manufacturing and development limitations inherent to traditional cell therapies. The company emphasizes the potential for same-day discharge and outpatient administration of its therapies, aiming to make cell therapy delivery more routine and accessible while addressing significant unmet medical needs in oncology and immunology.